Marginal zone lymphomas in children and the young adult population; characterization of genetic aberrations by FISH and RT-PCR by Rizzo, Kathryn A et al.
Marginal zone lymphomas in children and the young adult 
population; characterization of genetic aberrations by FISH and 
RT-PCR
Kathryn A Rizzo1,4, Berthold Streubel2, Stefania Pittaluga1, Andreas Chott3, Liqiang Xi1, 
Mark Raffeld1, and Elaine S Jaffe1
1Hematopathology Section, Laboratory of Pathology, Center for Cancer Research, National 
Cancer Institute, National Institutes of Health, Bethesda, MD, USA;
2Department of Pathology, Medical University of Vienna, Vienna, Austria
3Department of Pathology, Vienna General Hospital, Vienna, Austria
4Current address: Department of Pathology and Laboratory Medicine, Indiana University School 
of Medicine, Indianapolis, IN, USA
Abstract
Marginal zone lymphomas present rarely in children and young adults as either primary nodal or 
extranodal disease and have an excellent prognosis. To date, chromosomal aberrations have not 
been analyzed in the pediatric and young adult population. We undertook a study to analyze 
genetic alterations in nodal and extranodal marginal zone lymphomas in children and young adults 
using fluorescence in situ hybridization (FISH) and RT-PCR. These findings were correlated with 
clinical features at presentation and immunophenotype. Forty-one cases were identified meeting 
these criteria. The age range was 1.5–29 years old with 49% of the cases <18 years of age. 73% of 
the marginal zone lymphoma cases showed evidence of light chain restriction by 
immunohistochemistry or flow cytometry. CD43 was coexpressed in 83%. 85% of the marginal 
zone lymphoma cases tested showed evidence of immunoglobulin heavy chain gene 
rearrangement. Fifty-nine percent of the cases were nodal marginal zone lymphomas with a 
median age at presentation of 16 years and an M/F ratio of 7:1. Twenty-one percent of the nodal 
marginal zone lymphoma cases contained genetic aberrations. Seventeen percent contained 
trisomy 18 with one case containing an additional trisomy 3. A translocation of the 
immunoglobulin heavy chain gene to an unknown partner gene was present in one case. Forty-one 
percent of the cases were extranodal marginal zone lymphomas with a median age of 24 years and 
a M/F ratio of 1.4:1. Eighteen percent of the extranodal marginal zone lymphoma cases contained 
genetic aberrations. The t(14;18) involving the IGH and MALT1 genes was present in one case, 
tetraploidy was present in one case, and another case contained trisomy 3. Overall the incidence of 
genetic aberrations in marginal zone lymphomas in the pediatric and young adult population is 
low, but the aberrations seen are similar to those seen in the adult population.
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Marginal zone lymphomas are indolent lymphomas thought to arise at the post-germinal 
center stage of differentiation. They are morphologically and clinically heterogeneous. Three 
major categories are recognized in the 2008 WHO classification: nodal marginal zone 
lymphoma, extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue,and 
splenic marginal zone lymphoma. The modifier ‘B-cell’ as applied to marginal zone 
lymphoma has been eliminated from standard terminology, as these lymphomas are 
exclusively of B-cell derivation.1 In the adult population, extranodal marginal zone 
lymphomas (MALT lymphoma) occur more frequently than nodal marginal zone 
lymphomas, and extranodal marginal zone lymphomas are associated with specific genetic 
aberrations not present in nodal or splenic marginal zone lymphomas.2,3 Unlike other B-cell 
lymphomas such as follicular lymphoma and mantle cell lymphoma, marginal zone 
lymphomas lack a specific immunophenotype. Thus, the recognition of specific genetic 
aberrations might allow for greater diagnostic accuracy, or provide additional prognostic 
data. A well-documented example is the t(11;18)(q21;q21) in gastric MALT lymphomas.2 
The presence of this translocation is associated with a lack of regression of the lymphoma 
upon eradication of H. pylori.4,5
The extranodal marginal zone lymphoma-associated genetic aberrations also show variable 
frequency depending on the site of involvement.3,6 In the study from Streubel et al3 the 
t(11:18) (q21;q21) was most often found in pulmonary MALT lymphomas (53%) with an 
overall prevalence rate of 14%. The t(14;18)(q32;q21) involving the IGH and MALT1 genes 
had the highest prevalence in extranodal marginal zone lymphomas of the ocular adnexa 
(24%) with an overall rate of 11%. Trisomies 3 and 18 were shown to have an overall 
prevalence of 31 and 11%, respectively. Numerical chromosomal abnormalities, particularly 
gains of chromosome 3, are not specific for extranodal marginal zone lymphomas and can be 
seen in other B-cell malignancies including nodal marginal zone lym-phomas.7–12
Nodal marginal zone lymphoma in the pediatric and young adult population is relatively 
rare, with specific clinicopathological features that led to the delineation of pediatric nodal 
marginal zone lymphomas as a distinct entity in the 2008 WHO classification.1 Extranodal 
marginal zone lymphoma is rare in children, but otherwise resembles the disease seen in 
adults. The genetic aberrations seen in marginal zone lymphomas in the adult population 
have not been analyzed in a large cohort study in the pediatric and young adult age group. 
The aim of this study was to analyze all available cases of marginal zone lymphoma in the 
pediatric and young adult age group via RT-PCR and fluorescent in situ hybridization, and to 
correlate the results with immunophenotypic and molecular features.
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Materials and methods
Case Selection
We reviewed the files of the Hematopathology section of the Laboratory of Pathology, 
National Cancer Institute, National Institutes of Health from 1995 to 2006 for cases with a 
diagnosis of marginal zone lymphoma and age less then 30 years at presentation. All cases 
were submitted in consultation from outside physicians and the hematoxylin and eosin-
stained slides were reviewed. There were 22 newly identified cases, subsequent to the study 
by Taddesse-Heath et al,13 12 of which had material available for genetic studies. 29 cases 
previously reported had material available for genetic studies and were included in this 
study.
Immunohistochemistry
Immunohistochemical studies were performed to confirm the diagnosis of marginal zone 
lymphoma.We used fixed paraffin-embedded tissue sections by use of antigen retrieval 
methods on an automated immunostainer (Ventana Medical System, Tucson, AZ, USA), 
according to the manufacturer’s instruction. The antibodies analyzed included CD20 (L26), 
CD3, kappa, lambda, BCL-2, BCL-6, IgD (Dako, Carpinteria, CA, USA), CD10 
(Novocastra, Newcastle upon Tyne, UK) and CD43 (Becton Dickinson, San Jose, CA, 
USA). Light chain immunohistochem-ical staining was scored as showing either light chain 
restriction, or non-contributory if the neoplastic cells failed to stain for either kappa or 
lambda. A polytypic pattern was considered as evidence against a diagnosis of lymphoma.
Molecular Studies for Immunoglobulin Gene Rearrangement
Genomic DNA was extracted from formalin-fixed, paraffin-embedded tissue blocks. In some 
cases DNA was extracted using standard phenolchloroform methods, whereas in other cases 
tissue samples were sectioned on charged slides, depar-affinized with xylene, and hydrated 
before being scraped into polymerase chain reaction (PCR) tubes. The tissues were mixed 
with Gene Releaser resin (Bioventures, Murfreesboro, TN, USA) and preincubated in a 
Perkin Elmer 480 thermocycler (Applied Biosystems, Foster City, CA, USA) according to 
the manufacturer’s recommendations. To determine clonality of the immunoglobulin heavy 
chain gene, PCR was performed as previously described.14 Briefly, consensus primers to the 
conserved framework three (FR3) and the JH alpha regions of the immunoglobulin heavy 
chain gene were used in a Master Mix containing LD Taq DNA polymerase (Applied 
Biosystems) previously treated with Taq Start antibody (Clontech, Palo Alto, CA, USA). 
Additional seminested PCR amplification was performed using consensus primers to the 
conserved framework two (FR2) region of the immunoglobulin heavy chain gene, according 
to the method of Ramasamy et al.15 PCR products were analyzed using polyacrylamide gel 
electrophoresis as previously described.14 Cases negative for immunoglobulin heavy chain 
gene rearrangement for which paraffin blocks were available were further studied for 
rearrangements of the IGk locus using the Biomed II primer set described by van Dongen et 
al (Leukemia 17:2257–2237, 2003), and supplied by InVivoScribe Technologies (IGK Gene 
Clonality Assay—ABI Fluorescence Detection). These reactions interrogate rearrangements 
involving the Vk loci and Jk (Tube A), the Vk locus and the kDE locus (Tube B), and the k 
intron RSS locus and the kDE locus (Tube B). The products were analyzed by capillary 
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electrophoresis on an ABI 3130 Genetic Analyzer, and electropherograms were analyzed 
using GeneMapper software version 3.7 (ABI).
Detection of t(11;18)(q21;q21) by RT-PCR
RNA was isolated from archival formalin-fixed, paraffin-embedded lymphoma tissues. Total 
RNA was extracted from 10 mm sections with a high pure RNA paraffin kit (Roche 
Diagnostics, Mannheim, Germany). First-strand cDNA was synthesized from 1 μg total 
RNA with a superscript first-strand synthesis system (Invitrogen, Carlsbad, CA, USA) using 
random hexamers as primers. RT-PCR for the detection of the API2-MALT1 fusion 
transcript was performed according to Inagaki et al with one modification: first round RT-
PCR products were amplified in a second round separately and not as multiplex nested PCRs 
to discriminate the various fusion signals.16 Where indicated PCR products were sequenced 
using dRhodamine dye terminators on an ABI Prism 310 (PE Applied Biosystems, Foster 
City, CA, USA).
FISH Analysis
In all cases formalin-fixed paraffin-embedded tissue was used for FISH and RT-PCR studies. 
FISH was performed on Interphase cells with the following probe sets: for the detection of 
the t(14:18)(q32;q21) involving IGH and MALT1 P1 artificial chromosome (PAC) 152M5 
(SpectrumOrange labeled) spanning the MALT1 gene and flanking regions and bacterial 
artificial chromosome (BAC) 158A2 were used; for rearrangements of BCL10, BACs RP11–
1077C10 and RP11–36L4 centromeric to BCL10 and RP11–1080I1 and RP11–40K4 
telomeric to BCL10 were used. Translocations of FOXP1 were investigated with BACs 
RP11–154H23 and RP11–215K24, RP11–465K1 and RP11–335D10 for CNN3, RP11–
79K3 and RP11–77E14 for JMJD2C, RP11–13H20 and RP11–14K9 for ODZ2. 4 
Aberrations of IGH and BCL6 were examined with dual color break-apart probes (Vysis, 
Downer’s Grove, IL, USA). For the detection of trisomies 3, 12 and 18 we applied 
centromere-specific probes (Vysis). The cut-off value for the diagnosis of each probe set was 
the mean percentage of cells with a false-positive signal constellation plus 3 s.d., as assessed 
on tissue from 20 reactive lymph nodes. Fluorescence in situ hybridization (FISH) procedure 
was done according to published standard methods.17
Results
Characteristics of Newly Identified Cases
Twenty-two newly identified cases of marginal zone lymphoma were identified, and the 
clinical features are summarized in Table 1. The diagnosis of marginal zone lymphoma was 
established based on a mature B-cell neoplasm with clonal rearrangement of 
immunoglobulin genes in 20 of 22 cases. In 1 case PCR studies were negative for 
immunoglobulin gene rearrangement using FR3 and IgK probes, but no amplification was 
obtained with FR2. Both cases showed monoclonal expression of kappa light chain. The 
neoplastic cells lacked expression of CD10 and BCL6 in all cases studied. There were 13 
cases of nodal marginal zone lymphoma and nine cases of extranodal marginal zone 
lymphoma. The clinical features were similar to those of our previous series with all patients 
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presenting with a single site of disease (Stage 1). One patient had a recurrence of a 
conjunctival extranodal marginal zone lymphoma 1 year later.
Clinical and Immunohistochemical Characteristics of Study Cases
Of the 22 newly identified cases, 12 cases (five nodal, seven extranodal) had sufficient 
material for further genetic studies. In addition, 29 cases were selected from our previous 
study13 as having adequate material for further genetic studies. The age range in the 41 cases 
comprising the study cohort was 1.5–29 years with 49% of the cases ≤ 18 years of age. In 
all, 59% (24 cases) were nodal marginal zone lymphomas with a median age at presentation 
of 16 years and an M:F ratio of 7:1 (Table 2). Sixty-three percent (15 cases) were ≤ 18 years 
and consisted only of males. The most common location for nodal marginal zone lymphoma 
was cervical lymph nodes seen in 54% (13 cases) followed by inguinal lymph nodes in 13% 
(three cases) and submental in 8% (two cases). Co-expression of CD43 was present in 83% 
(15 of 18 cases), BCL-2 in 42% (5 of 12 cases) and IgD in 25% (5 of 20 cases). BCL-6 and 
CD10 were negative in all cases studied. Evidence of clonality in nodal marginal zone 
lymphomas was shown via immunoglobulin gene rearrangement in 22 of 24 cases (92%); 
the two negative cases had unsuccessful framework 2 amplification (1 case), and insufficient 
material for kappa probe analysis (1 case). Light chain restriction was shown by 
immunohistochemistry in 18 of 24 cases (Figure 1), with staining being inconclusive in the 
remaining six cases.
A total of 41% (17 cases) were extranodal marginal zone lymphomas (Table 3). The median 
age at presentation was 24 years, with an age range between 1.5 years and 29 years. The 
M:F ratio was 1.4:1 and 29% (five cases) were ≤ 18 years. The most common localization 
for extranodal marginal zone lymphomas was skin and soft tissue, seen in 35% (six cases). 
Co-expression of CD43 was present in 82% (9 of 11 cases), BCL-2 in 43% (three of seven 
cases) and IgD in 20% (2 of 10 cases). BCL-6 and CD10 were negative in all cases 
studied.Clonality was shown in 94% (16 of 17 cases) of the extranodal marginal zone 
lymphoma cases. Light chain restriction was present in 71% (12 cases) with lambda light 
chain restriction identified in only a single case presenting as an orbital mass. 
Immunoglobulin heavy chain gene rearrangement was present in 75% (12 of 16 cases). Two 
of the four negative cases did not have amplifiable DNA for framework 2 studies, and none 
of the four had additional material available for study with the kappa light chain probes. One 
case lacked light chain restriction and was negative by PCR, but showed Trisomy 3 by FISH 
(see below).
Marginal Zone Lymphoma Associated Genetic Aberrations
RT-PCR and FISH analyses for marginal zone lymphoma-associated genetic aberrations 
were performed on the 41 cases to detect the following aberrations: t(14;18)/IGH-MALT1, 
t(FOXP1), t(BCL10), trisomy3, trisomy18, t(ODZ2), t(JMJD2C) and t(CNN3) (Figure 1f).18 
In all, 21% of the 24 nodal marginal zone lymphomas analyzed contained genetic 
aberrations (Tables 2 and 4). Trisomy 18 occurred in 17% (4 of 23 cases), trisomy 3 
occurred in 4% (1 of 23 cases) and a t(IGH) to an unknown partner gene occurred in 4% (1 
of 23 cases). One case contained trisomies 3 and 18. Four of the five positive cases were 
found in patients less than 18 years of age.
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Genetic analysis was successfully performed on 17 cases of extranodal marginal zone 
lymphomas (Tables 3 and 4). Eighteen percent (three cases) contained genetic aberrations. 
The t(14;18) involving IGH and MALT1 genes was seen in 1 of 14 cases (7%). In one of the 
cases, which had not shown clonality via immunohistochemistry or immunoglobulin heavy 
chain gene rearrangement (case 19), trisomy 3 was present. For case 10, analyses on the 
thyroid and adjacent lymph node were performed.In this case, the adjacent lymph node 
showed tetraploidy and there was not enough material for FISH analysis on the thyroid 
specimen. Trisomy 18, which was relatively prevalent in the nodal marginal zone 
lymphomas, was not identified in the extranodal marginal zone lymphoma cases.
Discussion
We undertook this study to determine if genetic aberrations associated with marginal zone 
lymphomas in adults could be identified in similar lymphomas in the pediatric and young 
adult population. To accomplish these goals we used available paraffin-embedded sections 
from 12 newly identified cases reviewed in our laboratory, and 29 additional cases 
previously published.13 In addition, we were able to expand and reconfirm our previously 
reported clinicopathological experience with marginal zone lymphoma in the pediatric and 
young adult population. Genetic abnormalities were identified in both the nodal and 
extranodal marginal zone lymphoma cases, albeit at a low frequency (Table 4). Twenty-one 
percent of the cases of nodal marginal zone lymphomas showed a genetic change, most 
notably trisomy 18, seen in four cases (17%). The extranodal marginal zone lymphoma 
cases had a slightly lower incidence of genetic aberrations (18%). Trisomy 3 and tetraploidy 
were each seen in one case of extranodal marginal zone lymphoma. Numerical abnormalities 
of chromosomes 3 and 18 are relatively common in nodal and extranodal marginal zone 
lymphomas in adults.12
Only one case in each cohort showed evidence of an IGH translocation, with MALT1 being 
the partner in a single case involving the tonsil of a 1.5-year-old female. Streubel et al 
showed that the t(14;18) involving IGH/MALT1 had an incidence of 11% in extranodal 
cases analyzed in adults, with the highest frequency seen in the ocular adnexa/orbit (24%).3
The differential diagnosis of marginal zone lymphoma includes atypical marginal zone 
hyperplasia, which can present in mucosal-associated lymphoid tissue in Waldeyer’s ring or 
small intestine.19 In the report by Attygalle et al these cases all showed lambda light chain 
restriction, but failed to show evidence of clonality at the genetic level by PCR analysis for 
immunoglobulin heavy chain gene rearrangement. Our current study omitted cases which 
met these criteria. Seven cases of nodal marginal zone lymphoma expressed lambda, and 
immunoglobulin heavy chain gene clonality was confirmed in all seven cases. Only one 
extranodal marginal zone lymphoma expressed lambda, and this case presented as an orbital 
mass. Thus, we do not believe that a diagnosis of marginal zone hyperplasia is likely in our 
cases, or can account for the relatively low incidence of genetic aberrations seen. 
Nevertheless, one should be mindful of the differential diagnosis of marginal zone 
hyperplasia, which can present in both nodal and extranodal sites.20–22
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It has been shown that the clinical findings, histological presentation, immunophenotype and 
genetic aberrations of certain lymphomas differ between the adult and pediatric population.
23–26
 A recent review and synopses from the society of Hematopathology/European 
Association Haemato-pathology workshop illustrated these differences.23 Follicular 
lymphoma differs in the clinical, histological and immunophenotypical presentation between 
adults and pediatric patients. Pediatric follicular lymphoma cases are usually localized and 
curable, and may involve extranodal sites, including the testis.24,25 Histologically, they are 
more often grade 2 or 3 and a majority of them lack BCL-2 by immunohistochemical 
staining and BCL2 gene rearrangements.
The previous study by Taddesse-Heath et al analyzed the clinical and histological 
presentation of marginal zone lymphomas in young adults and children and found distinct 
characteristics not appreciated in the adult population.13 Our expanded study confirms 
previously reported features with nodal marginal zone lymphomas being more common than 
extranodal marginal zone lymphomas in this age group. This is in contrast to the adult 
population where extranodal marginal zone lymphomas is much more common than nodal 
marginal zone lymphomas.1 An excess of males over females was seen in both groups, 
contrasting with the usual female predominance seen typically in extranodal marginal zone 
lymphomas.2 For nodal marginal zone lymphomas the incidence in male and female patients 
is generally equal in the adult population.27–29
Table 5 summarizes the clinical features of previously reported cases and cases identified 
since our previous report. Almost half of the nodal marginal zone lymphoma cases presented 
in cervical lymph nodes, with another 10% in submandibular lymph nodes. Inguinal lymph 
node involvement was seen in 13% of patients. There was a marked male predominance, 
which was even more striking in patients under the age of 18, where the male/female ratio 
was 13:1. The extranodal marginal zone lymphoma cases showed a higher median age of 
presentation when compared with nodal marginal zone lymphomas, 23 vs 16 years. The 
most common site of involvement was the skin and soft tissue, seen in 28% of the cases. 
Two of the extranodal marginal zone lymphoma cases had involvement of adjacent lymph 
nodes.13
Marginal zone lymphomas lack a specific immu-noprofile, but immunohistochemical studies 
still provide some useful information. Co-expression of CD43 was seen in a majority of 
nodal and extranodal marginal zone lymphoma cases (88 and 80%, respectively). BCL-2 
positivity by immunohisto-chemistry was seen in over half of the nodal and extranodal 
marginal zone lymphoma cases and IgD was positive in a minority of the cases (20%). Light 
chain restriction could be shown in 70% of cases. However, it is preferable to confirm 
clonality by PCR for immunoglobulin gene rearrangement, and PCR studies are in fact more 
sensitive. IGk probe analysis is particularly useful for study of DNA extracted from paraffin 
blocks, as the quality of the DNA in such samples often does not permit use of framework 2 
probes, requiring DNA fragments of larger size.
Our study is the first to analyze genetic aberrations in nodal marginal zone lymphomas and 
extranodal marginal zone lymphomas occurring in the pediatric and young adult population. 
This larger cohort of cases confirms our previous observations regarding clinicopathological 
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features. Although the number of cases with aberrations was small, we detected no clinical 
differences in the cases with and without aberrations. The optimal clinical management for 
marginal zone lymphoma in this age group remains to be determined.Unfortunately, the 
nature of this referral population did not allow examination of long-term follow-up; 
however, local recurrence was reported in only one case.
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Figure 1. 
Histology, immunophenotype and FISH of marginal zone lymphoma. (a) H&E image of 
nodal marginal zone lymphoma. Residual germinal centers are surrounded by an atypical 
lymphoid proliferation. Magnification × 40. (b) At higher power lymphoid cells show a 
spectrum in cell size. Admixed eosinophils are present. Magnification × 400. (c) Atypical B-
cells show monotypic staining for lambda light chain by immunohistochemistry. Follicular 
colonization is present. Magnification × 200. (d) Staining for kappa is negative. 
Magnification × 200. (e) CD20 shows diffuse positivity and infiltration of the marginal zone. 
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(f) FISH of MALT1, IGH in a tonsillar extranodal marginal zone lymphoma. A red probe is 
utilized for MALT1, green probe for IGH. Both probes span the breakpoint, resulting in two 
fusion signals.
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Table 1
Clinical characteristics and clonality analysis of newly identified marginal zone lymphoma cases
Case Age Sex Lymph node/site IHC IG
Nodal marginal zone lymphoma cases
 1 17 M Submental K Clonal
 2 13 M Cervical L Clonal
 3 11 F Inguinal L Clonal
 4 15 F Inguinal K Clonal
 5 18 M Cervical L Clonal
 6 14 M Cervical NC Clonal
 7  6 M Axilla L Clonal
 8 17 M Cervical K Clonal
 9 17 M Cervical Ka Clonal
 10 22 M Cervical K Clonal
 11 16 M Inguinal K Clonal
 12 26 M Submandibular K Polyclonal
 13 29 M Submandibular NC Clonal
Extranodal marginal zone lymphoma cases
 1 24 M Soft tissue, scalp NC Clonal
 2 29 M Skin K Clonal
 3 23 M Adenoids K Clonal
 4 1.5 F Tonsils K Clonal
 5 16 M Soft tissue, head K Clonal
 6 17 F Skin, arm K Clonal
 7 27 M Skin, back K NA/Polyb
 8a 1O M Conjunctiva, left K Clonal
 8bc 11 M Conjunctiva, left K Clonal
 9 11 M Conjunctiva NC Clonal
NP, not performed; K, kappa light chain restriction; L, lambda light chain restriction; NC, non-contributory.
a
Light chain evaluation performed via flow cytometry.
bNo amplification seen in framework II, framework III and IgK showed no peaks.
cSame patient with a recurrence 1 year later.
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Table 2
Genetic characterization of nodal marginal zone lymphoma
Case Age Sex Lymph 
node site
RT-PCR FISH
2 13 M Cervical Negative Trisomies 3 & 18
5 18 M Cervical Negative Normal
7 6 M Axilla Negative Trisomy 18
10 22 M Cervical Negative Trisomy 18
11 16 M Inguinal Negative Normal
14a 20 M Preauricular Negative Normal
15a 16 M Cervical NA Normal
16a 19 M Cervical NA Normal
17a 17 M Submental Negative Normal
18a 22 M Cervical Negative Normal
19a 26 F Breast Negative Normal
20a 6 M Cervical NA Normal
21a 16 M Cervical Negative t(IGH), unknown partner gene
22a 16 M Cervical Negative Normal
23a 16 M Periparotid NA Normal
24a 14 M Cervical Negative Trisomy 18
25a 25 M Submental Negative Normal
26a 6 M Cervical Negative Normal
27a 24 F Inguinal NA Normal
28a 16 M Cervical NA Normal
29a 23 M Supraclavicular Negative Normal
30a 15 M Inguinal Negative Normal
31a 23 F Cervical Negative Normal
32a 15 M Submandibular Negative NA
aCases previously reported by Taddesse Heath et al.13
Negative, denotes negative for all known breakpoints; NA, tissue not available for analysis.
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Table 3
Genetic characterization of extranodal marginal zone lymphoma
Case Age Sex Site RT-PCR FISH
1 24 M Soft tissue, scalp Negative Normal
2 29 M Skin Negative Normal
3 23 M Adenoids Negative Normal
4 1.5 F Tonsils Negative t(14;18)
IGH-MALT1
6 17 F Skin, arm Negative NA
7 27 M Skin, back Negative Normal
9 11 M Conjunctiva Negative Normal
10aa 25 M Thyroid Negative NA
10ba Adjacent neck LN Negative Tetraploidy
11a 29 M Skin/subcutaneous,back
Negative Normal
12a 23 M Stomach Negative NA
13a 28 F Parotid NA Normal
14a 25 M Orbital mass Negative Normal
15a 27 F Skin, back Negative NA
16a 29 F Parotid gland & LN NA Normal
17a 10 M Lacrimal sac Negative Normal
18a 17 F Submandibular
salivary gland
Negative Normal
19a 22 F Conjunctiva NA Trisomy 3
aCases previously reported by Taddesse Heath et al.13
Negative, denotes negative for all known breakpoints; N.A., tissue not available for analysis; LN, lymph node.
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Table 4
Summary of genetic aberrations
Nodal marginal
zone lymphoma
Extranodal marginal
zone lymphoma
Total cases 24 (59%) 17 (41%)
Percentage of genetic
aberrations
21% (5/24) 18% (3/17)
Trisomy 18 17% (4/23) —
Trisomy 3 4% (1/23) 7% (1/14)
t(IGH), unknown
partner
4% (1/23)
—
t(14;18)IGH-MALT1 — 7% (1/14)
Tetraploidy — 7% (1/14)
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Table 5
Summary of the clinical characteristics at presentation including newly identified cases and those reported 
previously by Taddesse et al13
Nodal marginal
zone lymphoma
Extranodal marginal
zone lymphoma
Incidence 62% (39 total cases) 38% (24 total cases)
Median age 16 years old 23 years old
Overall M/F 7:1 1.7:1
Cases ≤18 years old 72% (28/39) 38% (9/24)
M/F (<18 years) 13:1 1.3:1
Common sites Cervical: 49% Skin/soft tissue: 29%
Inguinal: 13% Conjunctiva: 13%
Submandibular: 10% Orbital: 13%
Periparotid: 8% Parotid: 13%
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